Optibrium (PRIVATE.OPTIBRIUM)

Overall impact
C (48)

Commentary

Optibrium is an average overall performer. With a 'C' rating of 47.7 for overall impact (37th percentile compared to all companies), Optibrium ranks 46th out of 47 industry peers, behind Agilent, LGC Group, Pace Analytical Services and 42 others, and ahead of Catalent. On top material causes for Optibrium's industry (Life Sciences Tools & Services), Optibrium performs well in Child and Maternal Health (95.2 score), Disease Eradication (95.9), Technology Innovation (87.7) and 3 other causes where it received an 'A' score and performs poorly in Racial Justice and Civil Rights (25.9 score), Decent, Safe Work Opportunities (31.7), Reduced Green House Gas Emissions (14.1) and 8 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.OPTIBRIUM
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
52
Sector
Health Care
Industry
Life Sciences Tools & Services
Sub-industry
Life Sciences Tools & Services
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
United Kingdom
Share classes
PRIVATE.OPTIBRIUM
Description
Developer of a software technology intended to improve the efficiency and productivity of the drug discovery process. The company's software technology offers a guide to drug discovery through small-molecule designing, optimization and data analysis through its mobile and desktop application, thereby enabling clients to load a set of compound structures and browse data for their businesses.
Material causes
Ethos considers the following causes material for Optibrium, based on its industry sub-industry Life Sciences Tools & Services. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.